Clarivate Plc Stock Price, News & Analysis

Clarivate (NYSE:CLVT) has released its Trademark filing trends 2025 report, analyzing trademark registers across 10 major global markets. The report reveals that Mainland China leads global trademark filings with 6.76 million applications in 2024, followed by the U.S. (566,938) and India (537,000). Seven major brands - Procter & Gamble, Nestlé, Apple, L'Oréal, Novartis, LG Electronics and Unilever - consistently ranked among the top 20 largest portfolio owners across most registers.

Key findings show that France, Mainland China, and Japan experienced declining trademark filing activity for three consecutive years, reaching their lowest levels since 2017. Meanwhile, Australia saw a recovery in trademark filing volume, driven by a 24% increase in foreign-based brand owner applications in 2024. India demonstrated strong growth with an average yearly increase of 10% over the past decade.

Clarivate (NYSE:CLVT) has announced the integration of Pathway Maps into its OFF-X translational safety intelligence solution. This enhancement aims to streamline safety evaluations in drug development, addressing the critical issue where over 30% of drug development failures are attributed to safety concerns.

The new Pathway Maps feature provides visual tools that combine disease-specific signaling pathways and molecular processes with curated safety data, enabling researchers to quickly identify potential safety liabilities. This integration helps research teams make faster, more informed decisions during the drug development process, from early discovery to post-marketing surveillance.

The enhanced OFF-X platform, when combined with Cortellis Drug Discovery Intelligence, offers researchers a comprehensive approach to evaluate both efficacy and safety in drug development, helping reduce costly late-stage failures and accelerate time to market.

Clarivate reported mixed Q1 2025 financial results with total revenues of $593.7 million, down 4.4% from Q1 2024, while organic revenues showed a modest 0.3% increase. The company posted a net loss of $103.9 million ($0.15 per share), compared to a $75.0 million loss in Q1 2024.

Key highlights include:

• Organic recurring revenue growth of 0.6%
• Adjusted EBITDA of $233.2 million
• Free cash flow of $110.3 million
• $50 million in share repurchases

The company reaffirmed its 2025 outlook, projecting revenues between $2.28-2.40 billion and organic ACV growth of 1.0-2.0%. Despite macro volatility, management reported successful execution of their Value Creation Plan, with improved renewal rates and higher product usage in key areas.

Clarivate (NYSE: CLVT) has launched DRG Commercial Analytics 360, a new solution designed to help medtech companies enhance their commercial strategies through advanced data analytics. The platform combines Procedure Finder's search capabilities with Clarivate's provider and affiliations network to deliver comprehensive real-world intelligence.

The solution offers several key features:

• Integrated healthcare provider data and analytics for understanding patient treatment patterns and network affiliations
• De-duplicated market segments for accurate procedure volume tracking
• 360-degree market visibility with modularized claims and code groupings
• Expert-led data intelligence backed by medtech and healthcare specialists

The platform aims to help medtech companies optimize targeting, strategic planning, and patient access while enabling data-driven decision-making across commercial organizations.

Clarivate (NYSE: CLVT) has launched EndNote 2025, an enhanced reference management solution featuring AI-powered capabilities. The new release includes several key features: an AI-powered Key Takeaway tool for extracting research insights, an improved journal publishing matching tool, PDF citation functionality, and a redesigned summary panel.

Notable additions include Web of Science citing articles integration, streamlined reference updates, and full-text access tools. The company plans to introduce more AI features later in 2025, including the EndNote Research Assistant for subscribers. The solution operates on Clarivate's Academic AI Platform, facilitating AI deployment across their product portfolio.

Clarivate has announced a major expansion of its Academic AI Platform, introducing AI Agents to enhance academic workflows starting April 2025. The platform will feature new AI Agents, an Agent Builder, and community tools designed to boost productivity for researchers, students, and staff.

The first series of AI Agents includes a Literature Review tool launching April 10, 2025, through Web of Science Research Assistant, and Research Intelligence capabilities available to development partners by August 2025. The platform builds upon existing AI-powered tools already adopted by over 3,000 institutions.

The initiative includes development of an Agent Builder, a flexible environment requiring minimal coding expertise, allowing institutions to create and customize their own AI tools. The platform will also support community-built AI solutions, enabling institutions to share and collaborate on AI development.

Clarivate (NYSE: CLVT) has announced it will release its first quarter 2025 financial results on Tuesday, April 29, 2025, before market opening. The company will host a conference call and webcast at 9:00 AM Eastern Time on the same day to discuss the results.

The earnings release and supplementary financial information will be available on Clarivate's investor relations website. Interested parties can join the live webcast through the investor relations section or participate in the audio broadcast by calling 800-715-9871 (U.S.) or +1 646-307-1963 (international) using conference ID 7007526.

A replay of the webcast will be accessible on the investor relations website two hours after the call concludes and will remain available for one year.

Clarivate (NYSE:CLVT) has announced a strategic partnership with Iprova, integrating Iprova's invention creation solutions with IPfolio, Clarivate's IP management software. The partnership coincides with the release of Invention Studio 3, Iprova's enhanced AI-based invention creation tool hosted on Microsoft Azure.

The integration aims to streamline the transition of inventions into the patent workflow, creating a more collaborative environment for inventors and attorneys. The partnership represents Clarivate's commitment to improving the innovation economy by connecting knowledge and intellectual capital.

Additionally, Clarivate has acquired Rowan Patents, an AI-driven patent drafting software, further strengthening its position as a central hub for IP management. These strategic moves enhance Clarivate's ability to provide comprehensive support throughout the IP lifecycle, from invention creation to patent filing and prosecution.

Clarivate has unveiled its 2025 Top 100 Global Innovators list, highlighting organizations leading worldwide technology research and innovation. These elite companies generate $4.6 trillion in annual revenues, representing 4.4% of the global economy, with average innovation investment of 8.8% of their revenues totaling $290 billion USD.

Key findings include:

• Japan leads with 33 organizations, followed by US (18), Taiwan (13), Germany and South Korea (8 each)
• Samsung Electronics maintains #1 ranking
• Six new companies joined the list, including GE Aerospace and Caterpillar
• 16 organizations maintained all-time recipient status

New analysis reveals convergent inventions account for almost 40% of top innovations across five macro-forces: sustainability, wellbeing, mobility, connectivity, and automation. Electronics and computing equipment sector leads, followed by Semiconductors and Industrial systems.